Nuvectis Pharma Announces Positive Data for NXP800 in a Preclinical Model of ARID1a-Mutated Gastric Carcinoma
Nuvectis Pharma, Inc. recently announced positive data for NXP800 in a preclinical xenograft model of ARID1a-mutated gastric carcinoma.
“Following the strong preclinical proof of concept in ARID1a-mutated ovarian carcinoma models, we are very pleased with this new preclinical data for NXP800 in ARID1a-mutated gastric cancer, potentially expanding the development opportunity for NXP800 to an additional therapeutic area with a clear unmet need,” said Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis. “Out of approximately 26,000 people that receive a diagnosis of gastric cancer annually in the US, it is estimated that about 20%-25% have ARID1a-mutated tumors. Gastric cancer has a very poor prognosis with a 5-year survival rate limited to 32%. The NXP800 Phase 1a dose escalation study is progressing as planned and we expect to begin the Phase 1b portion of the study in Q1 2023.”
Key Results
- The study was conducted in a mouse model of ARID1a-mutated gastric cancer (SNU-1).
- Mice in each group were treated with either vehicle or NXP800 and tumor volumes were measured over 28 days.
- Treatment with NX800 resulted in tumor regression and substantial tumor growth inhibition versus the control.
Gastric cancer is the second most common cause of cancer death worldwide. The American Cancer Society estimates that there will be 26,380 new cases in the US in 2022, with most patients having advanced, non-resectable disease at the time of presentation. There is no universal standard therapy for patients with metastatic and unresectable disease, and treatments aimed at controlling tumor growth, symptom palliation and prolongation of survival include chemotherapy and chemotherapy-based regimens with immunotherapy or with radiation therapy. For patients whose cancers are HER2-positive, a HER2-targeted agent can be added to the treatment regimen. ARID1a mutation is detected in approximately 20-25% of cases of gastric cancer.
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. The company’s pipeline includes NXP800, a clinical-stage HSF1-pathway inhibitor, and NXP900, a SRC/YES1 kinase inhibitor in IND-enabling studies. For more information, visit www.nuvectis.com.
Total Page Views: 775
